Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$1.....
Bloomers!!!!
HUGE bid here!!
Moving up real, real soon...IMO!!!! To the solid Pennies and MORE!!
so right!!!!
and 1MM on the bid now!
wowzers...what up???
and it's gone.....
SOLID!!!
what filings?
already has IMO
Awesome volume and PPS movement so far today....WEEEEEEE!
What a volume explosion!!!
found where and by who?
I did and even let some go at .0003!!!! crazy
Maybe santa claus
YES!!!!
done!
rgbp having all the volume fun....need some here!
what makes you think that?
RGBP...thank me later!
Trading like a champ on price AND volume!!!!
Awesomeness!!!!!!
500k on the bid!!
Get them now peeps!
In 7 Thursdays!
Whatever interest THEY had has been contributed to REGEN!!! good stuff.
New 8k...hmmmmm:
Item 8.01 Other Events
On July 5, 2018 and July 3, 2018 respectively David Koos and Harry Lander assigned to Regen Biopharma, Inc. (“Regen”) their entire right , title and interest throughout the world in the inventions, improvements and all patent applications that are subject of an application for patent protection filed with the United States Patent and Trademark Office on June 14, 2018 entitled “Small Molecule Agonists and Antagonists of NR2F6 Activity” The abovementioned application relates to agonists and antagonists of nuclear receptor activity, specifically to the modulation ofNR2F6 activity and NR2F6 utilizing compounds, and the immune modulation and modulation of cancer stem cell activity through administration of compounds described within the application. David Koos currently serves as Chairman of the Board of Directors and Chief Executive Officer of Regen. Harry Lander currently serves as President and Chief Scientific Officer of Regen.
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
REGEN BIOPHARMA, INC.
Dated: 7/05/2018 By: /s/ David Koos
David Koos
Chief Executive Officer
New 8k...hmmmmm:
Item 8.01 Other Events
On July 5, 2018 and July 3, 2018 respectively David Koos and Harry Lander assigned to Regen Biopharma, Inc. (“Regen”) their entire right , title and interest throughout the world in the inventions, improvements and all patent applications that are subject of an application for patent protection filed with the United States Patent and Trademark Office on June 14, 2018 entitled “Small Molecule Agonists and Antagonists of NR2F6 Activity” The abovementioned application relates to agonists and antagonists of nuclear receptor activity, specifically to the modulation ofNR2F6 activity and NR2F6 utilizing compounds, and the immune modulation and modulation of cancer stem cell activity through administration of compounds described within the application. David Koos currently serves as Chairman of the Board of Directors and Chief Executive Officer of Regen. Harry Lander currently serves as President and Chief Scientific Officer of Regen.
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
REGEN BIOPHARMA, INC.
Dated: 7/05/2018 By: /s/ David Koos
David Koos
Chief Executive Officer
great and thx!!!
It IS coming!!!
As am I!!!!
Regen BioPharma, Inc. Nears Completion of Optimizing its Lead NR2F6 Small Molecule Agonist
Company is preparing for efficacy experiments in mice
SAN DIEGO, March 21, 2018 /PRNewswire/ --
Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) has been methodically optimizing small molecules that bind to, and activate, the NR2F6 nuclear receptor. The process is close to completion, with the primary and back up compounds being readied for final pre-clinical mouse experiments.
"We are currently preparing to test these compounds in different mouse models of autoimmunity. The final dosing experiments should be completed shortly and then we can move into efficacy studies in mice," says Harry Lander, Ph.D., MBA, President and Chief Scientific Officer of Regen.
"Having an optimized lead candidate is the culmination of a great deal of strategic planning and scientific work," says David Koos, Ph.D., Chairman & CEO Regen BioPharma Inc., "I am gratified that we are so close to achieving this important milestone and look forward to the next phase of drug development."
The NR2F6 nuclear receptor has been identified as a potentially very important immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator. The NR2F6 program at Regen aims to identify antagonists of NR2F6 in an effort to unleash the cancer-killing potential of a patient's own immune system as well as identifying agonists which should suppress the immune system in diseases where the immune system is over-activated, such as autoimmunity.
About Regen BioPharma Inc.
Regen BioPharma Inc. is a publicly traded biotechnology company (OTCQB: RGBP) and (OTCQB: RGBPP). The Company is focused on the immunology and immunotherapy space. The Company is focused on rapidly advancing novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is focused on small molecule therapies for treating cancer and autoimmune disorders. Additional information on Regen BioPharma is available at http://www.regenbiopharmainc.com.
Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
Contact Information
Regen BioPharma Inc.
David R. Koos, Ph.D.
Chairman & Chief Executive Officer
+1-619-702-1404 Phone
+1-619-330-2328 Fax
david.koos@regenbiopharma.com
Regen BioPharma, Inc. Nears Completion of Optimizing its Lead NR2F6 Small Molecule Agonist
Company is preparing for efficacy experiments in mice
SAN DIEGO, March 21, 2018 /PRNewswire/ --
Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) has been methodically optimizing small molecules that bind to, and activate, the NR2F6 nuclear receptor. The process is close to completion, with the primary and back up compounds being readied for final pre-clinical mouse experiments.
"We are currently preparing to test these compounds in different mouse models of autoimmunity. The final dosing experiments should be completed shortly and then we can move into efficacy studies in mice," says Harry Lander, Ph.D., MBA, President and Chief Scientific Officer of Regen.
"Having an optimized lead candidate is the culmination of a great deal of strategic planning and scientific work," says David Koos, Ph.D., Chairman & CEO Regen BioPharma Inc., "I am gratified that we are so close to achieving this important milestone and look forward to the next phase of drug development."
The NR2F6 nuclear receptor has been identified as a potentially very important immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator. The NR2F6 program at Regen aims to identify antagonists of NR2F6 in an effort to unleash the cancer-killing potential of a patient's own immune system as well as identifying agonists which should suppress the immune system in diseases where the immune system is over-activated, such as autoimmunity.
About Regen BioPharma Inc.
Regen BioPharma Inc. is a publicly traded biotechnology company (OTCQB: RGBP) and (OTCQB: RGBPP). The Company is focused on the immunology and immunotherapy space. The Company is focused on rapidly advancing novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is focused on small molecule therapies for treating cancer and autoimmune disorders. Additional information on Regen BioPharma is available at http://www.regenbiopharmainc.com.
Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
Contact Information
Regen BioPharma Inc.
David R. Koos, Ph.D.
Chairman & Chief Executive Officer
+1-619-702-1404 Phone
+1-619-330-2328 Fax
david.koos@regenbiopharma.com
Nice to hear from you...my thoughts exactly as well.
someone else is toooooooo!
for sure....it's Margin Call Monday!
That escalated quickly...make it 2,400
AT THIS RATE, 1400 TO THE MINUS BY DAY'S END.
I was just thinking and seeing the same!!! this gonna be a great year for us!!!